Blockade of human HERG K+ channels by rosiglitazone, an antidiabetic drug

Archives of Pharmacal Research

Volumn 35, Issue 9, 2012, Pages 1655-1664

  Lee, Seung Ho ^a   Sung, Min Ji ^a   Hahn, Sang June ^b   Kim, Jimok ^c   Min, Gyesik ^d   Jo, Su Hyun ^e   Choe, Han ^f   Choi, Bok Hee ^a  

^a Chonbuk National University Medical School   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d Gyeongsang National University   (South Korea)

^e Kangwon National University College of Medicine   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

Author keywords

Antidiabetic drug; Cardiotoxicity; HERG; Long QT syndrome; Rosiglitazone

Indexed keywords

POTASSIUM CHANNEL HERG; ROSIGLITAZONE;

ARTICLE; CHANNEL GATING; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; PATCH CLAMP; QT PROLONGATION;

ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; KINETICS; MEMBRANE POTENTIALS; OSMOLAR CONCENTRATION; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; RECOMBINANT PROTEINS; THIAZOLIDINEDIONES;

EID: 84872109571     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-0917-x     Document Type: Article

References (23)

1. Ahn, H. S., Kim, S. E., Jang, H. J., Kim, M. J., Rhie, D. J., Yoon, S. H., Jo, Y. H., Kim, M. S., Sung, K. W., Kim, S. Y., and Hahn, S. J., Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone. Naunyn Schmiedebergs Arch. Pharmacol., 374, 305-309 (2007).
2. Chapelsky, M. C., Thompson-Culkin, K., Miller, A. K., Sack, M., Blum, R., and Freed, M. I., Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J. Clin. Pharmacol., 43, 252-259 (2003).
3. Curran, M. E., Splawski, I., Timothy, K. W., Vincent, G. M., Green, E. D., and Keating, M. T., A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell, 80, 795-803 (1995).
4. Deeks, E. D. and Keam, S. J., Rosiglitazone : a review of its use in type 2 diabetes mellitus. Drugs, 67, 2747-2779 (2007).
5. Hamill, O. P., Marty, A., Neher, E., Sakmann, B., and Sigworth, F. J., Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch., 391, 85-100 (1981).
6. Hruska, M. W. and Frye, R. F., Simplified method for determination of rosiglitazone in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 803, 317-320 (2004).
7. Jeong, I., Choi, B., and Hahn, S., Rosiglitazone inhibits Kv 4.3 potassium channels by open-channel block and acceleration of closed-state inactivation. Br. J. Pharmacol., 163, 510-520 (2011).
8. Jo, S. H., Hong, H. K., Chong, S. H., Won, K. H., Jung, S. J., and Choe, H., Clomipramine block of the hERG K+ channel: accessibility to F656 and Y652. Eur. J. Pharmacol., 592, 19-25 (2008).
9. Knock, G. A., Mishra, S. K., and Aaronson, P. I., Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur. J. Pharmacol., 368, 103-109 (1999).
10. Kolte, B. L., Raut, B. B., Deo, A. A., Bagool, M. A., and Shinde, D. B., Liquid chromatographic method for the determination of rosiglitazone in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 788, 37-44 (2003).
11. Lee, S. Y., Kim, Y. J., Kim, K. T., Choe, H., and Jo, S. H., Blockade of HERG human K+ channels and IKr of guineapig cardiomyocytes by the antipsychotic drug clozapine. Br. J. Pharmacol., 148, 499-509 (2006).
12. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 270, 12953-12956 (1995).
13. Lu, L., Reiter, M. J., Xu, Y., Chicco, A., Greyson, C. R., and Schwartz, G. G., Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs. Diabetologia, 51, 675-685 (2008).
14. Mishra, S. K. and Aaronson, P. I., Differential block by troglitazone and rosiglitazone of glibenclamide-sensitive K+ current in rat aorta myocytes. Eur. J. Pharmacol., 386, 121-125 (1999).
15. Nissen, S. E. and Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med., 356, 2457-2471 (2007).
16. Sanguinetti, M. C. and Jurkiewicz, N. K., Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol., 96, 195-215 (1990).
17. Suessbrich, H., Schonherr, R., Heinemann, S. H., Attali, B., Lang, F., and Busch, A. E., The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br. J. Pharmacol., 120, 968-974 (1997).
18. Suessbrich, H., Waldegger, S., Lang, F., and Busch, A. E., Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett., 385, 77-80 (1996).
19. Taglialatela, M., Castaldo, P., Pannaccione, A., Giorgio, G., and Annunziato, L., Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets: present and future implications. Biochem. Pharmacol., 55, 1741- 1746 (1998).
20. Trudeau, M. C., Warmke, J. W., Ganetzky, B., and Robertson, G. A., HERG, a human inward rectifier in the voltage-gated potassium channel family. Science, 269, 92-95 (1995).
21. Viskin, S., Long QT syndromes and torsade de pointes. Lancet, 354, 1625-1633 (1999).
22. Wagstaff, A. J. and Goa, K. L., Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs, 62, 1805-1837 (2002).
23. Zhou, Z., Gong, Q., Ye, B., Fan, Z., Makielski, J. C., Robertson, G. A., and January, C. T., Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys. J., 74, 230-241 (1998).